title: Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
abstract: Crizotinib is a multitarget tyrosine kinase inhibitor and it represents the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Crizotinib is generally well tolerated and the most frequent adverse events include gastrointestinal effects, visual disorders, edema, fatigue and liver enzyme abnormalities. However, due to the increasing clinical experience with crizotinib, other toxicities are emerging, such as Q-wave T-wave interval prolongation and bradycardia. In the current review we will focus on the management of crizotinib-related cardiotoxicity.
authors.affiliation: Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028 Rionero in Vulture (PZ), Italy.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Tartarone
authors.affiliation: Cardiology Unit, Department of Onco-Hematology IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Gallucci
authors.affiliation: Department of Oncology, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Lazzari
authors.affiliation: Hospital Pharmacy, Department of Onco-Hematology IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Lerose
authors.affiliation: Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028 Rionero in Vulture (PZ), Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Lombardi
authors.affiliation: Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028 Rionero in Vulture (PZ), Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D066126:Cardiotoxicity / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D000077547:Crizotinib; D004347:Drug Interactions; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK-positive non-small-cell lung cancer; cardiotoxicity; crizotinib; drug interactions